Back to Browse Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 4

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis

Authors Vincenzo Savica, Domenico Santoro, Paolo Monardo, Agostino Mallamace, Guido Bellinghieri

Published 8 August 2008 Volume 2008:4(4) Pages 821—826


Review by Single-blind

Peer reviewer comments 3

Vincenzo Savica1,2, Domenico Santoro1, Paolo Monardo2, Agostino Mallamace1, Guido Bellinghieri1

1Experimental and Clinic Department of Internal Medicine and Pharmacology, University of Messina, Italy; 2Nephrology and Dialysis Unit, Papardo Hospital, Messina, Italy

Abstract: Sevelamer carbonate is an anion exchange pharmaceutical, developed to improve on the performance of the non-absorbable, non-calcium, and metal-free phosphate binder sevelamer hydrochloride. Sevelamer carbonate is expected not to worsen metabolic acidosis, as previously reported during long-term treatment with sevelamer hydrochloride in hemodialysis (HD) patients. Carbonate is the alternate counterion to chloride on the sevelamer polymeric backbone, but the active poly(allylamine) responsible for phosphate (PO4) binding remains unaltered. Therefore, sevelamer carbonate is expected to reduce elevated serum phosphorus level, similarly to sevelamer hydrochloride. Sevelamers are prescribed in uremic HD patients to control hyperphosphatemia, but the carbonate has also been proposed for the treatment of chronic kidney disease (CKD) non-dialysis patients. Although hyperphosphatemia is regarded as a main contributor to increased mortality in the HD population because of cardiovascular calcification, metabolic acidosis has also been advocated as a major player in the increased mortality in this population, by engendering malnutrition, negative nitrogen balance, and inflammation. This paper reviews the evidence showing that sevelamer carbonate is as good as sevelamer hydrochloride in terms of hyperphosphatemia control in CKD, but with a better outcome in serum bicarbonate balance.

Keywords: chronic kidney disease, sevelamer carbonate, hyperphosphatemia, hemodialysis

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

An MRI-visible non-viral vector for targeted Bcl-2 siRNA delivery to neuroblastoma

Shen M, Gong FM, Pang PF, Zhu KS, Meng XC, Wu C, Wang J, Shan H, Shuai XT

International Journal of Nanomedicine 2012, 7:3319-3332

Published Date: 2 July 2012

Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering

Chen YP, Zheng XW, Chen G, He C, Zhu WF, Feng SY, Xi G, Chen R, Lan FH, Zeng HS

International Journal of Nanomedicine 2012, 7:73-82

Published Date: 30 December 2011

Diagnosis of hepatoma using grayscale and Doppler ultrasound in patients with chronic liver disease

Memon WA, Haider Z, Beg MA, Idris M, Tanveer-ul-Haq, Akhtar W, Idris S

International Journal of General Medicine 2011, 4:751-754

Published Date: 31 October 2011

Comparison of disposable sutureless silicone ring and traditional metal ring in 23-gauge vitrectomy combined with cataract surgery

Wu J-G, Wei R-H, Liu A-H, Zhou X-X, Sun G-L, Li X-R

Clinical Ophthalmology 2011, 5:901-905

Published Date: 30 June 2011

Drug discovery and development for neglected diseases: the DNDi model

Eric Chatelain, Jean-Robert Ioset

Drug Design, Development and Therapy 2011, 5:175-181

Published Date: 16 March 2011